Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2013 Aug 23;12(2):327–333.e1. doi: 10.1016/j.cgh.2013.08.034

Figure 1.

Figure 1

Distribution of IL28B genotype (rs12980275) by treatment eligibility. Segments 1 and 2 represent subgroups of patients considered ineligible for antiviral treatment. Of these, approximately 40% had a favorable IL28B genotype (segment 1). One fourth of the patients had a favorable genotype and also was eligible for treatment (segment 3). However, a significant proportion of patients without any major treatment exclusion had an unfavorable IL28B genotype (segment 4).